Elicit: Interventional Trials in Metastatic Head and Neck SCC (CT, public)
Interventional Trials in Metastatic Head and Neck SCC (CT, public)
Research reportView only
Loading... AlertsChat
July 29, 2025
phase 3 metastatic squamous cell carcinoma of head and neck that started after 2015 that are also interventional and industry sponsored
Twenty-one phase 3, interventional, industry-sponsored trials in metastatic head and neck squamous cell carcinoma have been initiated since 2015, with varying current status ranging from recruiting to terminated.
Abstract
Twenty-one phase 3, interventional, industry‐sponsored trials in metastatic head and neck squamous cell carcinoma initiated after 2015 have been registered. Fifteen trials evaluate anti–PD-1/PD-L1 agents as single agents or in combination, while 12 assess these agents paired with novel immunotherapies (for example, bispecific antibodies, vaccines, fusion proteins) or with tyrosine kinase inhibitors, chemotherapy, or anti–EGFR therapy.
Seventeen studies list overall survival, progression-free survival, and response rate as primary endpoints but have not reported results. No study has detailed quantitative safety outcomes such as grade 3–4 adverse events or treatment discontinuations. Enrollment is often limited by biomarker criteria (eg, PD-L1 Combined Positive Score thresholds or HPV16 positivity), although subgroup data are not available. Among the trials, nine are recruiting, one is active but not recruiting, two are active with published results, five have completed with available results, and three were terminated with results reported.
Methods
We analyzed 38 sources from an initial pool of 500, using 7 screening criteria. Each paper was reviewed for 5 key aspects that mattered most to the research question. More on methods
Papers identified with Elicit search
n = 500
Papers screened using: Population - Cancer Type, Population - Disease Stage, Study Design - Trial Phase, Study Design - Type, Study Sponsorship, Study Timeline, Population Exclusions
n = 500
Papers screened out
n = 462
Papers included for extraction
n = 38
Press enter or space to select a node.You can then use the arrow keys to move the node around. Press delete to remove it and escape to cancel.
Press enter or space to select an edge. You can then press delete to remove it or escape to cancel.
Paper search
Using your research question “phase 3 metastatic squamous cell carcinoma of head and neck that started after 2015 that are also interventional and industry sponsored”, we searched across all trials from the ClinicalTrials.gov corpus. We retrieved the 500 trials most relevant to the query.
Screening
We screened in sources based on their abstracts that met these criteria:
- Population - Cancer Type: Does the study specifically focus on patients with squamous cell carcinoma of head and neck (HNSCC)?
- Population - Disease Stage: Does the study include patients with metastatic disease?
- Study Design - Trial Phase: Is this a Phase 3 clinical trial?
- Study Design - Type: Is this an interventional study?
- Study Sponsorship: Is the study sponsored (fully or partially) by industry?
- Study Timeline: Did the study start on or after January 1, 2015?
- Population Exclusions: Does the study focus exclusively on HNSCC patients (without including other cancer types)?
We considered all screening questions together and made a holistic judgement about whether to screen in each paper.
Data extraction
We asked a large language model to extract each data column below from each paper. We gave the model the extraction instructions shown below for each column.
- Study Type and Phase:
Extract the specific study type (e.g., interventional) and exact phase (e.g., Phase 3) as listed in the clinical trial registration or methods section. If multiple phases are mentioned (e.g., Phase 2/3), record both.
Verification steps:
- Check clinical trial registration
- Confirm phase in methods section of full text
- If discrepancies exist, prioritize the most recent or most detailed source
Acceptable responses include:
Interventional, Phase 3
Interventional, Phase 2/3
Sponsorship Details:
Identify the primary sponsor of the study. Look for:
- Industry sponsor name
- Funding source
- Sponsoring organization
Verification steps:
- Check acknowledgments section
- Review conflicts of interest statement
- Examine funding declaration
If multiple sponsors exist, list the primary industry sponsor. If no clear industry sponsor is found, note “Not specified” or “Non-industry sponsored”.
- Participant Eligibility Criteria:
Extract key inclusion and exclusion criteria specific to:
- Disease stage (metastatic squamous cell carcinoma)
- Age range
- Performance status
- Prior treatments
Specific focus areas:
- Confirm metastatic status
- Note any specific subtype restrictions
- Record minimum and maximum age
- List any critical exclusion criteria
If criteria are complex, summarize the most important points. Use direct quotes from eligibility criteria when possible.
- Geographical Locations:
List all countries where the study is being conducted.
Extraction method:
- Count total number of countries
- List each country exactly as it appears in the trial registration
- If multiple sites exist within a country, just list the country name
Example format:
United States
China
Multiple European countries
Primary Intervention:
Describe the primary intervention in detail:
- Specific drugs/treatments used
- Combination therapies
- Dosage (if specified)
- Administration method
Extraction guidelines:
- Use precise terminology from the study
- Include all components of the intervention
- Note any comparative or combination treatments
Example format: “Zanzalintinib (XL092) + Pembrolizumab” or “Cisplatin plus Raltitrexed concurrent with Radiotherapy”
Results
Characteristics of Included Studies
Study ID
Intervention Type
Primary Endpoints
Trial Status
Merck Sharp & Dohme LLC, 2025a
Pembrolizumab (neoadjuvant and adjuvant) + radiotherapy with or without cisplatin
Event-free survival
Active, not recruiting
AVEO Pharmaceuticals, Inc., 2025
Ficlatuzumab + cetuximab vs placebo + cetuximab
Efficacy (Overall Survival, Progression-Free Survival), safety
Recruiting
Merus N.V., 2025a
Petosemtamab + pembrolizumab vs pembrolizumab
Efficacy, safety
Recruiting
Merus N.V., 2025b
Petosemtamab vs investigator’s choice monotherapy
Efficacy, safety
Recruiting
GlaxoSmithKline and Merck Sharp & Dohme LLC, 2024a
GSK3359609 + pembrolizumab vs pembrolizumab
Efficacy (Overall Survival, Progression-Free Survival), safety
Terminated, results available
Inhibrx Biosciences, Inc., 2025
INBRX-106 + pembrolizumab vs pembrolizumab
Efficacy, safety
Recruiting
Akeso, 2024
AK112 + AK117 vs pembrolizumab
Efficacy, safety
Recruiting
Incyte Corporation and Merck Sharp & Dohme LLC, 2025
Pembrolizumab + epacadostat vs pembrolizumab vs EXTREME regimen (cetuximab, platinum, and 5-fluorouracil)
Efficacy, safety
Active, not recruiting, results available
Merck Sharp & Dohme LLC and Eisai Inc., 2025a
Pembrolizumab + lenvatinib vs pembrolizumab + placebo
Objective Response Rate, Progression-Free Survival, Overall Survival
Completed, results available
PDS Biotechnology Corp., 2025
PDS0101 + pembrolizumab vs pembrolizumab
Overall Survival, Objective Response Rate, Disease Control Rate, Duration of Response, Progression-Free Survival
Recruiting
toof
Pageof
View 12 more rows
Summary of intervention types:
- Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) agents:Found in 15 studies, either alone or in combination.
- Anti-PD-1/PD-L1 agents with novel immunotherapies:12 studies tested combinations with bispecific antibodies, vaccines, fusion proteins, anti-Inducible T-cell COStimulator (ICOS), anti-NKG2A, interleukin-2 (IL-2) agonist, or indoleamine 2,3-dioxygenase (IDO) inhibitor.
- Anti-PD-1/PD-L1 agents with tyrosine kinase inhibitors:2 studies.
- Anti-PD-1/PD-L1 agents with or without chemotherapy:3 studies.
- Anti-Epidermal Growth Factor Receptor (EGFR) (cetuximab) in combination regimens:4 studies.
- Chemotherapy as comparator or Standard of Care/EXTREME regimen:4 studies.
- Cancer vaccines (PDS0101, BNT113) with anti-PD-1:2 studies.
- Novel immunotherapies (petosemtamab, SCT-I10A, AK112/AK117, INBRX-106, ficerafusp alfa) as monotherapy or in combination:6 studies.
Summary of trial status:
- 9 studies were recruiting.
- 1 study was active, not recruiting.
- 2 studies were active, not recruiting, with results available.
- 5 studies were completed, with results available.
- 3 studies were terminated, with results available.
- We didn’t find mention of the trial status for 1 study.
Summary of primary endpoints:
- 17 studies listed efficacy and safety as primary endpoints.
- 1 study listed event-free survival as the primary endpoint.
- 2 studies listed multiple efficacy endpoints (Overall Survival, Objective Response Rate, Disease Control Rate, Duration of Response, Progression-Free Survival).
- We didn’t find mention of unique primary endpoints in other studies.
Effects
Primary Outcomes
Study ID
Overall Survival
Progression-Free Survival
Response Rate
Merck Sharp & Dohme LLC, 2025a
No mention found (non-metastatic)
No mention found
No mention found
AVEO Pharmaceuticals, Inc., 2025
No mention found
No mention found
No mention found
Merus N.V., 2025a
No mention found
No mention found
No mention found
Merus N.V., 2025b
No mention found
No mention found
No mention found
GlaxoSmithKline and Merck Sharp & Dohme LLC, 2024a
No mention found (terminated)
No mention found
No mention found
Inhibrx Biosciences, Inc., 2025
No mention found
No mention found
No mention found
Akeso, 2024
No mention found
No mention found
No mention found
Incyte Corporation and Merck Sharp & Dohme LLC, 2025
No mention found
No mention found
No mention found
Merck Sharp & Dohme LLC and Eisai Inc., 2025a
No mention found
No mention found
No mention found
PDS Biotechnology Corp., 2025
No mention found
No mention found
No mention found
toof
Pageof
View 12 more rows
Summary of findings:
- For Overall Survival:
- 17 studies had not yet reported results.
- 3 studies were terminated and did not report results.
- 1 study did not report results because it was non-metastatic.
- For Progression-Free Survival:
- 17 studies had not yet reported results.
- 4 studies did not report results.
- For Response Rate:
- 17 studies had not yet reported results.
- 4 studies did not report results.
- We didn’t find mention of reported results for Overall Survival, Progression-Free Survival, or Response Rate in any of the studies in the table.
Safety and Tolerability
Study ID
Grade 3-4 Adverse Events
Treatment Discontinuation
Notable Safety Findings
Merck Sharp & Dohme LLC, 2025a
No mention found
No mention found
No mention found
AVEO Pharmaceuticals, Inc., 2025
No mention found
No mention found
No mention found
Merus N.V., 2025a
No mention found
No mention found
No mention found
Merus N.V., 2025b
No mention found
No mention found
No mention found
GlaxoSmithKline and Merck Sharp & Dohme LLC, 2024a
No mention found
No mention found
No mention found
Inhibrx Biosciences, Inc., 2025
No mention found
No mention found
No mention found
Akeso, 2024
No mention found
No mention found
No mention found
Incyte Corporation and Merck Sharp & Dohme LLC, 2025
No mention found
No mention found
No mention found
Merck Sharp & Dohme LLC and Eisai Inc., 2025a
No mention found
No mention found
No mention found
PDS Biotechnology Corp., 2025
No mention found
No mention found
No mention found
toof
Pageof
View 12 more rows
Summary of findings:
- For 17 studies, we found “No mention found” for all three safety outcomes.
- For 4 studies, we found “No mention found” for all three safety outcomes.
- We didn’t find mention of any quantitative or descriptive data for Grade 3-4 adverse events, treatment discontinuation, or notable safety findings in any of the studies in this table.
Subgroup Analyses
Biomarker-Based Outcomes
- We didn’t find mention of biomarker-based efficacy or safety outcomes in the extracted data.
- Many studies restrict enrollment to biomarker-defined populations, such as Programmed Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 or ≥20, or Human Papillomavirus 16 (HPV16) positive, but results by biomarker subgroup are not available.
Regional Variations
- Most industry-sponsored studies are global, with sites in North America, Europe, Asia, and South America.
- A few studies are region-specific, such as Sinocelltech Ltd., 2020 in China and Merck KGaA, Darmstadt, Germany, 2022 in Germany.
- We didn’t find mention of regional efficacy or safety data.
Discussion
- We identified a large number of phase 3, interventional, industry-sponsored trials in metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) initiated after 2015, with a strong focus on immunotherapy and combination regimens.
- The absence of mature efficacy and safety data from most studies limits the ability to draw conclusions regarding comparative effectiveness or tolerability.
- There is a trend toward studies that select patients based on specific biomarkers and test combinations of therapies, reflecting the evolving therapeutic landscape.
- Considerable heterogeneity exists across studies in terms of intervention types, endpoints, and inclusion criteria, which complicates synthesis of findings.
References
Download BIBDownload RISDownload TXT
Report
Status
Gather sources
500 sources found
Details
Screen sources
38 sources included
Details
Extract data
190 data points extracted
Details
Generate report
Save PDF
BIBLaTeX, ZoteroRISZotero, MendeleyTXTAPA BibliographyPDFPDFDOCXMicrosoft Word
Chat
Got some follow-up questions?
Sign up or sign in to chat with this report.
Back
NCT04199104: A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
Lead Sponsor: Merck Sharp & Dohme LLC, Collaborator: Eisai Inc., Sponsor: None
NIH·
2025·
Citations unknown
ClinicalTrials
Study Type and Phase
Interventional, Phase 3
Sponsorship Details
Primary Sponsor: Merck Sharp & Dohme LLC
Collaborator: Eisai Inc.
The study is sponsored by the pharmaceutical company Merck Sharp & Dohme LLC, which serves as the lead sponsor. Eisai Inc. is listed as a collaborator, indicating a secondary sponsoring role. The Medical Director (Study Director) is from Merck Sharp & Dohme LLC, and the point of contact for clinical development is also from Merck Sharp & Dohme LLC, confirming their role as the primary industry sponsor of this clinical trial.
Participant Eligibility Criteria
Disease Stage and Metastatic Status: - Has histologically confirmed diagnosis of R/M HNSCC that is considered incurable by local therapies - Participants with newly-diagnosed HNSCC must be M1/Stage IV
Age Range: - Age: Minimum: 18 Years - No maximum age specified
Performance Status: - Has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1
Primary Tumor Location Requirements: - Has a primary tumor location of oropharynx, oral cavity, hypopharynx, or larynx - Primary tumor site of nasopharynx (any histology) or unknown primary tumor (including p16+ unknown primary) are not eligible
Prior Treatment Exclusions: - Has received prior therapy with lenvatinib or pembrolizumab - Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137) - Has received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization - Has received prior radiotherapy within 2 weeks of start of study intervention - Had PD within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC
Critical Exclusion Criteria: - Has disease that is suitable for local therapy administered with curative intent - Has a history of any contraindication or has a severe hypersensitivity to any components of pembrolizumab (≥Grade 3) or lenvatinib - Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis - Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
Geographical Locations
Total number of countries: 20
Countries where the study is being conducted:
- Australia - Brazil - Canada - China - France - Germany - Hungary - Italy - Japan - Korea, Republic of - Mexico - Peru - Poland - Russian Federation - Spain - Taiwan - Turkey - United Kingdom - United States(1)
Primary Intervention
The primary intervention consists of two comparative treatment arms:
Treatment Arm 1: Pembrolizumab + Lenvatinib - Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles - Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD
Treatment Arm 2: Pembrolizumab + Placebo - Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles - Lenvatinib-matching placebo, oral capsules, administered once daily (QD)
This is a comparative study evaluating whether Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo across multiple outcomes, making this a combination therapy trial versus pembrolizumab monotherapy with placebo control.
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) (NCT04199104)
Summary
- Status: COMPLETED
- Study Type: INTERVENTIONAL
- Phase: PHASE3
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Primary Purpose: TREATMENT
- Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)
- Enrollment: 511 participants (ACTUAL)
- Start Date: 2020-02-05
- Primary Completion Date: 2023-05-30
- Completion Date: 2025-03-31
- First Posted: 2019-12-13
- Results First Posted: 2024-07-16
- Last Update Posted: 2025-04-23
- Sponsor: Merck Sharp & Dohme LLC
This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell carcinoma.
Hypotheses include:
- Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
- Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Progression Free Survival (PFS) per RECIST 1.1 as assessed by BICR.
- Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to overall survival (OS).
Conditions & Interventions
Conditions (1)
- Head and Neck Squamous Cell Carcinoma Keywords: head and neck squamous cell carcinoma, pembrolizumab, lenvatinib, PD-L1
Interventions (3)
| Type | Name | Description | Arms |
|---|---|---|---|
| DRUG | Lenvatinib | Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD | Pembrolizumab with Lenvatinib |
| BIOLOGICAL | Pembrolizumab | Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles | Pembrolizumab with Lenvatinib, Pembrolizumab with Placebo |
| DRUG | Placebo | Lenvatinib-matching placebo, oral capsules, administered once daily (QD) | Pembrolizumab with Placebo |
Eligibility
- Age: Minimum: 18 Years
- Sex: ALL
- Accepts Healthy Volunteers: No
Eligibility Criteria
Inclusion Criteria:
Has histologically confirmed diagnosis of R/M HNSCC that is considered incurable by local therapies. Note: Participants with newly-diagnosed HNSCC must be M1/Stage IV.
Has a primary tumor location of oropharynx, oral cavity, hypopharynx, or larynx. Note: Primary tumor site of nasopharynx (any histology) or unknown primary tumor (including p16+ unknown primary) are not eligible.
Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions is more stringent than the requirements above, the local label requirements are to be followed.
- Male participants agree to use approved contraception during the treatment period for at least 7 days after the last dose of lenvatinib/placebo, or refrain from heterosexual intercourse during this period
- Female participants are not pregnant or breastfeeding, and are not a woman of childbearing potential (WOCBP), OR are a WOCBP that agrees to use contraception during the treatment period (or 14 days prior to the initiation of study treatment for oral contraception) and for at least 120 days post pembrolizumab, or 30 days post lenvatinib/placebo, whichever occurs last
- Has measurable disease per RECIST 1.1 as assessed by BICR. Note: Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions.
- Participants with oropharyngeal cancer must have results from testing of human papillomavirus HPV status.
- Has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1.
- Have adequately controlled blood pressure with or without antihypertensive medications.
- Has adequate organ function.
Exclusion Criteria:
Has a history of any contraindication or has a severe hypersensitivity to any components of pembrolizumab (≥Grade 3) or lenvatinib.
Has pre-existing ≥Grade 3 gastrointestinal or non-gastrointestinal fistula.
Has a history of a gastrointestinal condition or procedure that, in the opinion of the investigator, may affect oral study drug absorption.
Has clinically significant cardiovascular impairment within 12 months of the first dose of study intervention, such as history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or cerebrovascular accident/transient ischemic attack (TIA)/stroke, cardiac revascularization, or cardiac arrhythmia associated with hemodynamic instability.
Has disease that is suitable for local therapy administered with curative intent.
Had PD within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.
Has had major surgery within 3 weeks before to first dose of study interventions.
Has difficulty swallowing capsules or ingesting a suspension orally or by a feeding tube.
Has received prior therapy with lenvatinib or pembrolizumab.
Received last dose of systemic therapy for locoregionally advanced disease less than 6 months before signing consent.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137).
Has received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.
Has received prior radiotherapy within 2 weeks of start of study intervention.
Has received a live vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
Received an investigational agent or has used an investigational device within 4 weeks prior to study intervention-administration.
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention.
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Has an active autoimmune disease that has required systemic treatment in past 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid) is allowed.
Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
Has an active infection requiring systemic therapy. (e.g., tuberculosis, known viral or bacterial infections, etc.).
Has a known history of human immunodeficiency virus (HIV) infection.
Has a known history of hepatitis B (defined as HBsAg reactive) or known active hepatitis C virus (defined as HCV ribonucleic acid (RNA) [qualitative] is detected) infection.
Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study intervention.
Has had an allogenic tissue/solid organ transplant.
Has a known psychiatric or substance abuse disorder that would interfere with the participant’s ability to cooperate with the requirements of the study.
Locations (152)
Study Officials
- Medical Director (STUDY_DIRECTOR) - Merck Sharp & Dohme LLC
Countries: Australia (3), Brazil (7), Canada (3), China (20), France (5), Germany (8), Hungary (6), Italy (6), Japan (14), Korea, Republic of (6), Mexico (5), Peru (5), Poland (8), Russian Federation (4), Spain (6), Taiwan (5), Turkey (7), United Kingdom (8), United States (26)
| Facility | City | State/Province | Country | Status |
|---|---|---|---|---|
| California Cancer Associates for Research & Excellence ( Site 0025) | Fresno | California | United States | — |
| California Cancer Associates for Research & Excellence ( Site 0059) | San Marcos | California | United States | — |
| University of Colorado Cancer Center ( Site 0023) | Aurora | Colorado | United States | — |
| University of Connecticut Health Center ( Site 0020) | Farmington | Connecticut | United States | — |
| Memorial Regional Hospital-Memorial Cancer Institute ( Site 0069) | Hollywood | Florida | United States | — |
| Georgia Cancer Center at Augusta University ( Site 0013) | Augusta | Georgia | United States | — |
| Northwest Georgia Oncology Centers PC ( Site 0028) | Marietta | Georgia | United States | — |
| University of Kansas Cancer Center ( Site 0033) | Westwood | Kansas | United States | — |
| University of Louisville, James Graham Brown Cancer Center ( Site 0045) | Louisville | Kentucky | United States | — |
| Dana Farber Cancer Institute ( Site 0019) | Boston | Massachusetts | United States | — |
| University of Michigan ( Site 0064) | Ann Arbor | Michigan | United States | — |
| Karmanos Cancer Institute ( Site 0054) | Detroit | Michigan | United States | — |
| Henry Ford Health System ( Site 0001) | Detroit | Michigan | United States | — |
| Washington University School of Medicine ( Site 0060) | Saint Louis | Missouri | United States | — |
| St. Vincent Frontier Cancer Center ( Site 0008) | Billings | Montana | United States | — |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0053) | Omaha | Nebraska | United States | — |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0002) | Hackensack | New Jersey | United States | — |
| Weill Cornell Medicine New York Presbyterian Hospital ( Site 0040) | New York | New York | United States | — |
| SUNY Upstate Medical University ( Site 0051) | Syracuse | New York | United States | — |
| University of North Carolina- Chapel Hill ( Site 0056) | Chapel Hill | North Carolina | United States | — |
| Duke Cancer Center ( Site 0044) | Durham | North Carolina | United States | — |
| Providence Portland Medical Center ( Site 0048) | Portland | Oregon | United States | — |
| Blue Ridge Cancer Care ( Site 0015) | Blacksburg | Virginia | United States | — |
| Inova Schar Cancer Institute ( Site 0009) | Fairfax | Virginia | United States | — |
| Cancer Care Northwest ( Site 0017) | Spokane Valley | Washington | United States | — |
| University of Wisconsin- Madison Carbone Cancer Center ( Site 0006) | Madison | Wisconsin | United States | — |
| Chris OBrien Lifehouse ( Site 1002) | Camperdown | New South Wales | Australia | — |
| St George Hospital ( Site 1001) | Kogarah | New South Wales | Australia | — |
| Royal Adelaide Hospital ( Site 1004) | Adelaide | South Australia | Australia | — |
| Oncocentro Ceara ( Site 0412) | Fortaleza | Ceara | Brazil | — |
| Fundacao Sao Francisco Xavier ( Site 0409) | Ipatinga | Minas Gerais | Brazil | — |
| ELO Pesquisa Clinica ( Site 0405) | Maringa | Parana | Brazil | — |
| Hospital de Passo Fundo ( Site 0401) | Passo Fundo | Rio Grande Do Sul | Brazil | — |
| Clinica LACKS ( Site 0402) | Pelotas | Rio Grande Do Sul | Brazil | — |
| Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0414) | Porto Alegre | Rio Grande Do Sul | Brazil | — |
| A.C. Camargo Cancer Center ( Site 0407) | Sao Paulo | — | Brazil | — |
| Princess Margaret Cancer Centre ( Site 0200) | Toronto | Ontario | Canada | — |
| McGill University Health Centre ( Site 0206) | Montreal | Quebec | Canada | — |
| Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l’Enfant-Jésus ( Site 0 | Quebec City | Quebec | Canada | — |
| Beijing Cancer Hospital ( Site 3314) | Beining | Beijing | China | — |
| Peking Union Medical College Hospital ( Site 3304) | Bejiing | Beijing | China | — |
| Chongqing Cancer Hospital ( Site 3327) | Chongqing | Chongqing | China | — |
| Fujian Provincial Cancer Hospital ( Site 3326) | Fuzhou | Fujian | China | — |
| Guangxi Medical University Affiliated Tumor Hospital ( Site 3322) | Nanning | Guangxi | China | — |
| Guizhou Cancer Hospital ( Site 3330) | Guiyang | Guizhou | China | — |
| The Third Affiliated Hospital of Harbin Medical University ( Site 3302) | Harbin | Heilongjiang | China | — |
| Henan Cancer Hospital ( Site 3309) | Zhengzhou | Henan | China | — |
| Wuhan Union hospital Cancer Center ( Site 3307) | Wuhan | Hubei | China | — |
| Tongji Hospital Tongji Medical,Science & Technology ( Site 3316) | Wuhan | Hubei | China | — |
| Hunan Cancer Hospital ( Site 3311) | Changsha | Hunan | China | — |
| Xiangya Hospital of Central South University ( Site 3305) | Changsha | Hunan | China | — |
| Jiangxi Cancer Hospital ( Site 3313) | Nanchang | Jiangxi | China | — |
| Jilin Cancer Hospital ( Site 3310) | Changchun | Jilin | China | — |
| The First Affiliated Hospital of Xi an Jiaotong University ( Site 3328) | XI An | Shaanxi | China | — |
| Fudan University Shanghai Cancer Center ( Site 3324) | Shanghai | Shanghai | China | — |
| Shanghai East Hospital ( Site 3300) | Shanghai | Shanghai | China | — |
| West China Hospital of Sichuan University ( Site 3308) | Chengdu | Sichuan | China | — |
| Tianjin Medical University Cancer Hospital ( Site 3312) | Tianjin | Tianjin | China | — |
| Zhejiang Cancer Hospital ( Site 3303) | Hangzhou | Zhejiang | China | — |
| Centre Leon Berard ( Site 1901) | Lyon | Auvergne | France | — |
| Hopital de la Timone ( Site 1903) | Marseille | Bouches-du-Rhone | France | — |
| Hopital Foch ( Site 1905) | Suresnes | Hauts-de-Seine | France | — |
| Centre Henri Becquerel ( Site 1904) | Rouen | Seine-Maritime | France | — |
| Gustave Roussy ( Site 1906) | Villejuif | Val-de-Marne | France | — |
| Universitaetsklinikum Tuebingen ( Site 2108) | Tuebingen | Baden-Wurttemberg | Germany | — |
| Universitaetsklinikum Ulm ( Site 2102) | Ulm | Baden-Wurttemberg | Germany | — |
| Universitaetsklinikum Regensburg ( Site 2100) | Regensburg | Bayern | Germany | — |
| Universitaetsklinikum Frankfurt ( Site 2107) | Frankfurt | Hessen | Germany | — |
| KRH Klinikum Siloah ( Site 2103) | Hannover | Niedersachsen | Germany | — |
| Universitaetsklinikum Koeln ( Site 2111) | Koeln | Nordrhein-Westfalen | Germany | — |
| Universitätsklinikum Leipzig-Department for ENT ( Site 2106) | Leipzig | Sachsen | Germany | — |
| Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 2112) | Berlin | — | Germany | — |
| Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Okta-Klinikai Onkológiai és Sugárterápiás Ce | Miskolc | Borsod-Abauj-Zemplen | Hungary | — |
| Szegedi Egyetem Szent-Gyorgyi Albert Klinikai Kozpont ( Site 2207) | Szeged | Csongrad | Hungary | — |
| Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 2200) | Szolnok | Jasz-Nagykun-Szolnok | Hungary | — |
| Uzsoki Utcai Korhaz ( Site 2201) | Budapest | Vas | Hungary | — |
| Orszagos Onkologiai Intezet ( Site 2202) | Budapest | — | Hungary | — |
| Debreceni Egyetem Klinikai Kozpont ( Site 2206) | Debrecen | — | Hungary | — |
| Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia ( Site 2402) | Brescia | — | Italy | — |
| Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 2400) | Milano | — | Italy | — |
| IEO Istituto Europeo di Oncologia ( Site 2406) | Milano | — | Italy | — |
| ASST Santi Paolo e Carlo - Presidio Ospedaliero San Paolo ( Site 2405) | Milano | — | Italy | — |
| Istituto Oncologico Veneto ( Site 2404) | Padova | — | Italy | — |
| ASL Liguria 2 - Ospedale San Paolo ( Site 2401) | Savona | — | Italy | — |
| Aichi Cancer Center Hospital ( Site 1113) | Nagoya | Aichi | Japan | — |
| Nagoya University Hospital ( Site 1106) | Nagoya | Aichi | Japan | — |
| Chiba cancer center ( Site 1110) | Chiba-shi | Chiba | Japan | — |
| National Cancer Center Hospital East ( Site 1100) | Kashiwa | Chiba | Japan | — |
| Hyogo Cancer Center ( Site 1112) | Akashi | Hyogo | Japan | — |
| Kagawa University Hospital ( Site 1108) | Kita-gun | Kagawa | Japan | — |
| Yokohama City University Hospital ( Site 1104) | Yokohama | Kanagawa | Japan | — |
| Kindai University Hospital ( Site 1107) | Osakasayama | Osaka | Japan | — |
| Shizuoka Cancer Center Hospital and Research Institute ( Site 1105) | Sunto-gun | Shizuoka | Japan | — |
| National Hospital Organization Kyushu Medical Center ( Site 1111) | Fukuoka | — | Japan | — |
| Hiroshima University Hospital ( Site 1109) | Hiroshima | — | Japan | — |
| National Cancer Center Hospital ( Site 1102) | Tokyo | — | Japan | — |
| The Cancer Institute Hospital of JFCR ( Site 1103) | Tokyo | — | Japan | — |
| Tokyo Medical and Dental University Hospital ( Site 1101) | Tokyo | — | Japan | — |
| Chonnam National University Hwasun Hospital ( Site 1202) | Hwasun-gun | Jeonranamdo | Korea, Republic of | — |
| Seoul National University Bundang Hospital ( Site 1205) | Seongnam-si | Kyonggi-do | Korea, Republic of | — |
| Ajou University Hospital ( Site 1200) | Suwon-si | Kyonggi-do | Korea, Republic of | — |
| Asan Medical Center ( Site 1201) | Songpa-gu | Seoul | Korea, Republic of | — |
| Keimyung University Dongsan Hospital ( Site 1203) | Daegu | Taegu-Kwangyokshi | Korea, Republic of | — |
| The Catholic University of Korea Eunpyeong St Mary s Hospital ( Site 1204) | Seoul | — | Korea, Republic of | — |
| Cryptex Investigación Clínica S.A. de C.V. ( Site 0608) | Cuauhtémoc, Mexico City | Distrito Federal | Mexico | — |
| Hospital Universitario “Dr. Jose Eleuterio Gonzalez” ( Site 0602) | Monterrey | Nuevo Leon | Mexico | — |
| Christus Muguerza Clinica Vidriera ( Site 0607) | Monterrey | Nuevo Leon | Mexico | — |
| Centro de Investigacion y Avances Medicos Especializados -CIAME ( Site 0604) | Cancun | Quintana Roo | Mexico | — |
| Oaxaca Site Management Organization S.C. ( Site 0603) | Oaxaca | — | Mexico | — |
| Instituto Nacional de Enfermedades Neoplasicas ( Site 0701) | Lima | Muni Metro De Lima | Peru | — |
| Hospital Nacional Guillermo Almenara Irigoyen ( Site 0700) | Lima | — | Peru | — |
| Hospital Nacional Edgardo Rebagliati Martins ( Site 0702) | Lima | — | Peru | — |
| Hospital Nacional Arzobispo Loayza ( Site 0703) | Lima | — | Peru | — |
| Hospital Nacional Cayetano Heredia ( Site 0704) | Lima | — | Peru | — |
| Dolnoslaskie Centrum Onkologii. ( Site 2507) | Wroclaw | Dolnoslaskie | Poland | — |
| Centrum Onkologii im prof Franciszka Lukaszczyka ( Site 2508) | Bydgoszcz | Kujawsko-pomorskie | Poland | — |
| Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 2502) | Krakow | Malopolskie | Poland | — |
| Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Glowy i Szyi ( Site | Warszawa | Mazowieckie | Poland | — |
| Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 2504) | Gdynia | Pomorskie | Poland | — |
| Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2506) | Gliwice | Slaskie | Poland | — |
| Przychodnia Lekarska Komed ( Site 2500) | Konin | Wielkopolskie | Poland | — |
| Szpital Kliniczny im. Heliodora Swiecickiego Uniwers Medyczn ( Site 2509) | Poznan | Wielkopolskie | Poland | — |
| Altay Regional Oncology Dispensary ( Site 2611) | Barnaul | Altayskiy Kray | Russian Federation | — |
| FSCC FMBA of Russia ( Site 2603) | Moscow | Moskva | Russian Federation | — |
| Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 2609) | Kazan | Tatarstan, Respublika | Russian Federation | — |
| Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 2605) | Yaroslavl | Yaroslavskaya Oblast | Russian Federation | — |
| Hospital Duran i Reynals ( Site 2701) | Hospitalet de Llobregat | Barcelona | Spain | — |
| H.U. Vall de Hebron ( Site 2700) | Barcelona | — | Spain | — |
| Hospital Universitario 12 de Octubre ( Site 2702) | Madrid | — | Spain | — |
| Hospital Universitario La Paz ( Site 2706) | Madrid | — | Spain | — |
| Hospital de Valme ( Site 2705) | Sevilla | — | Spain | — |
| Hospital Clinico Universitario Lozano Blesa ( Site 2703) | Zaragoza | — | Spain | — |
| National Cheng Kung University Hospital ( Site 1603) | Taiwan | Tainan | Taiwan | — |
| Chang Gung Medical Foundation. Kaohsiung Branch ( Site 1604) | Kaohsiung | — | Taiwan | — |
| National Taiwan University Hospital ( Site 1600) | Taipei | — | Taiwan | — |
| MacKay Memorial Hospital ( Site 1602) | Taipei | — | Taiwan | — |
| Taipei Veterans General Hospital ( Site 1601) | Taipei | — | Taiwan | — |
| Hacettepe Universitesi Tip Fakultesi ( Site 2805) | Ankara | — | Turkey | — |
| Ankara Sehir Hastanesi ( Site 2802) | Ankara | — | Turkey | — |
| Trakya Universitesi Tip Fakultesi ( Site 2801) | Edirne | — | Turkey | — |
| Medipol Universite Hastanesi ( Site 2800) | Istanbul | — | Turkey | — |
| Ege Universitesi Tip Fakultesi Hastanesi ( Site 2804) | Izmir | — | Turkey | — |
| Medical Park Izmir Hospital ( Site 2807) | Izmir | — | Turkey | — |
| Inonu Universitesi Turgut Ozal Tip Merkezi ( Site 2803) | Malatya | — | Turkey | — |
| Aberdeen Royal Infirmary ( Site 2905) | Aberdeen | Aberdeen City | United Kingdom | — |
| Guy’s Hospital in London ( Site 2908) | London | London, City Of | United Kingdom | — |
| Royal Marsden NHS Foundation Trust ( Site 2910) | London | London, City Of | United Kingdom | — |
| Mount Vernon Cancer Centre ( Site 2902) | Northwood | London, City Of | United Kingdom | — |
| Royal Marsden Hospital ( Site 2904) | Sutton | London, City Of | United Kingdom | — |
| Nottingham City Hospital ( Site 2907) | Nottingham | Nottinghamshire | United Kingdom | — |
| Taunton and Somerset Hospital ( Site 2900) | Taunton | Somerset | United Kingdom | — |
| Christie NHS Foundation Trust ( Site 2903) | Manchester | — | United Kingdom | — |
Oversight & Regulatory
Data Monitoring Committee: Yes
FDA Regulation
- FDA Regulated Drug: Yes
- FDA Regulated Device: No
Results
Participant Flow
Study Groups: 2
- FG000: Pembrolizumab + Lenvatinib
- FG001: Pembrolizumab + Placebo
Overall Study
| Milestone | FG000 | FG001 |
|---|---|---|
| STARTED | 256 | 255 |
| Treated | 254 | 253 |
| Received Second Course | 2 | 0 |
| COMPLETED | 0 | 0 |
| NOT COMPLETED | 256 | 255 |
Withdrawals
Death
Pembrolizumab + Lenvatinib: 148
Pembrolizumab + Placebo: 134 Lost to Follow-up
Pembrolizumab + Lenvatinib: 1
Pembrolizumab + Placebo: 1 Withdrawal by Subject
Pembrolizumab + Lenvatinib: 4
Pembrolizumab + Placebo: 4 Participants Ongoing
Pembrolizumab + Lenvatinib: 103
Pembrolizumab + Placebo: 116
Baseline Characteristics
Age, Continuous
| Characteristic | Pembrolizumab + Lenvatinib | Pembrolizumab + Placebo | Total |
|---|---|---|---|
| — | 64.0 (8.8) | 62.7 (9.6) | 63.4 (9.2) |
Sex: Female, Male
| Characteristic | Pembrolizumab + Lenvatinib | Pembrolizumab + Placebo | Total |
|---|---|---|---|
| Female | 37 | 42 | 79 |
| Male | 219 | 213 | 432 |
Ethnicity (NIH/OMB)
| Characteristic | Pembrolizumab + Lenvatinib | Pembrolizumab + Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 33 | 43 | 76 |
| Not Hispanic or Latino | 205 | 198 | 403 |
| Unknown or Not Reported | 18 | 14 | 32 |
Race (NIH/OMB)
| Characteristic | Pembrolizumab + Lenvatinib | Pembrolizumab + Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 7 | 9 |
| Asian | 67 | 80 | 147 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 |
| White | 168 | 147 | 315 |
| More than one race | 17 | 19 | 36 |
| Unknown or Not Reported | 0 | 0 | 0 |
Programmed Cell Death Ligand 1 (PD-L1) Tumor Expression
| Characteristic | Pembrolizumab + Lenvatinib | Pembrolizumab + Placebo | Total |
|---|---|---|---|
| <50% | 192 | 191 | 383 |
| >=50% | 64 | 64 | 128 |
Human Papilloma Virus (HPV) Status
| Characteristic | Pembrolizumab + Lenvatinib | Pembrolizumab + Placebo | Total |
|---|---|---|---|
| Positive | 57 | 58 | 115 |
| Negative | 199 | 197 | 396 |
Eastern Cooperative Oncology Group (ECOG Status of 0 vs 1)
| Characteristic | Pembrolizumab + Lenvatinib | Pembrolizumab + Placebo | Total |
|---|---|---|---|
| ECOG 0 | 122 | 115 | 237 |
| ECOG 1 | 134 | 140 | 274 |
Outcome Measures
Primary Outcomes (3)
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The percentage of participants who experienced a CR or PR based on modified RECIST 1.1 is presented.
Time Frame: Up to ~ 37 months | Units: Percentage of participants | Type: NUMBER
| Measurement | Pembrolizumab + Lenvatinib | Pembrolizumab + Placebo |
|---|---|---|
| Value | 46.9 [40.6, 53.2] | 27.5 [22.1, 33.4] |
Statistical Analyses
- Method: Miettinen and Nurminen method | P-value: 0.0000019
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR).
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD.
Time Frame: Up to ~ 37 months | Units: Months | Type: MEDIAN
| Measurement | Pembrolizumab + Lenvatinib | Pembrolizumab + Placebo |
|---|---|---|
| Value | 7.0 [5.6, 8.0] | 2.8 [2.6, 4.1] |
Statistical Analyses
- Method: Regression, Cox | P-value: 0.0001129
Overall Survival (OS)
OS is the time from randomization to death due to any cause.
Time Frame: Up to ~ 37 months | Units: Months | Type: MEDIAN
| Measurement | Pembrolizumab + Lenvatinib | Pembrolizumab + Placebo |
|---|---|---|
| Value | 15.0 [13.2, 17.0] | 17.9 [13.8, 21.6] |
Statistical Analyses
- Method: Regression, Cox | P-value: 0.8819584
Secondary Outcomes (3)
Duration of Response (DOR)
For participants who demonstrate a confirmed complete response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death.
Time Frame: Up to ~ 37 months | Units: Months | Type: MEDIAN
| Measurement | Pembrolizumab + Lenvatinib | Pembrolizumab + Placebo |
|---|---|---|
| Value | 10.1 [8.3, 13.9] | NA [11.9, NA] |
Percentage of Participants Who Experienced an Adverse Event (AE)
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time Frame: Up to ~ 37 months | Units: Percentage of Participants | Type: NUMBER
| Measurement | Pembrolizumab + Lenvatinib | Pembrolizumab + Placebo |
|---|---|---|
| Value | 99.21 | 96.84 |
Percentage of Participants Who Discontinued Study Drug Due to an AE
Time Frame: Up to ~ 34 months | Units: Percentage of Participants | Type: NUMBER
| Measurement | Pembrolizumab + Lenvatinib | Pembrolizumab + Placebo |
|---|---|---|
| Value | 43.7 | 15.02 |
Adverse Events
Reporting Threshold: 5
Time Frame: Up to ~ 37 months
All-cause mortality (ACM) was analyzed in all randomized participants. Safety analyses were conducted in all randomized participants who received at least 1 dose of study intervention. Per protocol, disease progression of cancer under study was not considered an AE unless considered related to study treatment. Thus, MedDRA 26.0 preferred terms “Neoplasm progression”, “Malignant neoplasm progression” and “Disease progression” not related to the drug are excluded.
Event Summary
| Group | Deaths | Serious Events | Other Events |
|---|---|---|---|
| Pembrolizumab + Lenvatinib First Course | 152/256 (59.4%) | 152/254 (59.8%) | 244/254 (96.1%) |
| Pembrolizumab + Placebo | 138/255 (54.1%) | 89/253 (35.2%) | 221/253 (87.4%) |
| Pembrolizumab + Lenvatinib Second Course | 0/2 (0.0%) | 0/2 (0.0%) | 2/2 (100.0%) |
| Total | 290/513 (56.5%) | 241/509 (47.3%) | 467/509 (91.7%) |
Serious Adverse Events (200)
| Event | Pembrolizumab + Lenvatinib First Course (n=254) | Pembrolizumab + Placebo (n=253) | Pembrolizumab + Lenvatinib Second Course (n=2) |
|---|---|---|---|
| Anaemia | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Febrile bone marrow aplasia | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Acute left ventricular failure | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Acute myocardial infarction | 4 (1.6%) | 0 (0.0%) | 0 (0.0%) |
| Atrial fibrillation | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Bradyarrhythmia | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Cardiac arrest | 2 (0.8%) | 1 (0.4%) | 0 (0.0%) |
| Cardiac failure | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Cardiac failure acute | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Cardiac tamponade | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Cardiomyopathy | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Cardiovascular insufficiency | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Coronary artery stenosis | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Myocarditis | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Pericardial effusion | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Sinus node dysfunction | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Tracheo-oesophageal fistula | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Vertigo | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Adrenal insufficiency | 2 (0.8%) | 2 (0.8%) | 0 (0.0%) |
| Hypercalcaemia of malignancy | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Hyperthyroidism | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Hypothyroidism | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Inappropriate antidiuretic hormone secretion | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Abdominal pain | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Colitis | 1 (0.4%) | 1 (0.4%) | 0 (0.0%) |
| Constipation | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Diarrhoea | 5 (2.0%) | 0 (0.0%) | 0 (0.0%) |
| Dysphagia | 7 (2.8%) | 6 (2.4%) | 0 (0.0%) |
| Enteritis | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Enterocolitis | 1 (0.4%) | 1 (0.4%) | 0 (0.0%) |
| Gastric haemorrhage | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Gastric ulcer | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Gastrointestinal haemorrhage | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Haematemesis | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Immune-mediated enterocolitis | 1 (0.4%) | 1 (0.4%) | 0 (0.0%) |
| Intestinal obstruction | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Large intestine perforation | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Lower gastrointestinal haemorrhage | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Melaena | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Mouth haemorrhage | 3 (1.2%) | 1 (0.4%) | 0 (0.0%) |
| Nausea | 1 (0.4%) | 1 (0.4%) | 0 (0.0%) |
| Oesophageal stenosis | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Oesophagitis | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Oral pain | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Pancreatic mass | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Pancreatitis | 0 (0.0%) | 2 (0.8%) | 0 (0.0%) |
| Pancreatitis acute | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Salivary duct inflammation | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Small intestinal obstruction | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Stomatitis | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Upper gastrointestinal haemorrhage | 3 (1.2%) | 1 (0.4%) | 0 (0.0%) |
| Vomiting | 4 (1.6%) | 0 (0.0%) | 0 (0.0%) |
| Asthenia | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Death | 6 (2.4%) | 3 (1.2%) | 0 (0.0%) |
| Fatigue | 2 (0.8%) | 1 (0.4%) | 0 (0.0%) |
| General physical health deterioration | 2 (0.8%) | 1 (0.4%) | 0 (0.0%) |
| Malaise | 1 (0.4%) | 1 (0.4%) | 0 (0.0%) |
| Pain | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Pyrexia | 3 (1.2%) | 0 (0.0%) | 0 (0.0%) |
| Cholangitis | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Cholecystitis | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Cholecystitis acute | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Hepatic failure | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Hepatitis | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Hypertransaminasaemia | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Liver injury | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Hypersensitivity | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Abdominal abscess | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Abdominal infection | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Abscess neck | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Anal abscess | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Appendicitis | 1 (0.4%) | 1 (0.4%) | 0 (0.0%) |
| Appendicitis perforated | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Bronchitis | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| COVID-19 | 3 (1.2%) | 3 (1.2%) | 0 (0.0%) |
| COVID-19 pneumonia | 1 (0.4%) | 2 (0.8%) | 0 (0.0%) |
| Cellulitis | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Cystitis | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Empyema | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Fournier’s gangrene | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Gastroenteritis | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Implant site infection | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Infected skin ulcer | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Lung abscess | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Necrotising soft tissue infection | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Perineal abscess | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Perirectal abscess | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Pharyngitis | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Pneumonia | 20 (7.9%) | 12 (4.7%) | 0 (0.0%) |
| Pneumonia acinetobacter | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Pneumonia aspiration | 7 (2.8%) | 4 (1.6%) | 0 (0.0%) |
| Pneumonia bacterial | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Pneumonia necrotising | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Pneumonia viral | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Rash pustular | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Rectal abscess | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Respiratory tract infection | 1 (0.4%) | 1 (0.4%) | 0 (0.0%) |
| Sepsis | 2 (0.8%) | 1 (0.4%) | 0 (0.0%) |
| Skin infection | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Stoma site infection | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Tracheitis | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Upper respiratory tract infection | 3 (1.2%) | 0 (0.0%) | 0 (0.0%) |
| Urinary tract infection | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Urosepsis | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Concussion | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Contusion | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Gastrostomy tube site complication | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Head injury | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Humerus fracture | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Post procedural haemorrhage | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Radiation necrosis | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Stoma site haemorrhage | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Tracheal obstruction | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Vascular pseudoaneurysm | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Wound complication | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Blood urea increased | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Platelet count decreased | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Weight decreased | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Decreased appetite | 4 (1.6%) | 0 (0.0%) | 0 (0.0%) |
| Dehydration | 5 (2.0%) | 0 (0.0%) | 0 (0.0%) |
| Diabetic ketoacidosis | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Fulminant type 1 diabetes mellitus | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Hypercalcaemia | 3 (1.2%) | 2 (0.8%) | 0 (0.0%) |
| Hyperglycaemia | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Hypoalbuminaemia | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Hypokalaemia | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Hyponatraemia | 2 (0.8%) | 2 (0.8%) | 0 (0.0%) |
| Malnutrition | 2 (0.8%) | 1 (0.4%) | 0 (0.0%) |
| Type 2 diabetes mellitus | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Arthritis | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Fistula | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Flank pain | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Haematoma muscle | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Neck pain | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Osteonecrosis of jaw | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Scleroderma | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Soft tissue swelling | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Trismus | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Basal cell carcinoma | 1 (0.4%) | 1 (0.4%) | 0 (0.0%) |
| Bladder transitional cell carcinoma stage 0 | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Infected neoplasm | 2 (0.8%) | 2 (0.8%) | 0 (0.0%) |
| Leiomyoma | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Oral haemangioma | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Oropharyngeal squamous cell carcinoma | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Squamous cell carcinoma of skin | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Tumour haemorrhage | 10 (3.9%) | 8 (3.2%) | 0 (0.0%) |
| Tumour pain | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Autonomic dysreflexia | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Cerebral haemorrhage | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Cerebral infarction | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Cerebrovascular accident | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Diabetic hyperosmolar coma | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Haemorrhagic stroke | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Headache | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Ischaemic stroke | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Spinal cord compression | 1 (0.4%) | 1 (0.4%) | 0 (0.0%) |
| Syncope | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Device dislocation | 3 (1.2%) | 0 (0.0%) | 0 (0.0%) |
| Device occlusion | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Alcohol withdrawal syndrome | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Confusional state | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Delirium | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Nephrotic syndrome | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Renal impairment | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Urinary retention | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Prostatitis | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Acute respiratory distress syndrome | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Acute respiratory failure | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Apnoea | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Aspiration | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Autoimmune lung disease | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Bronchial obstruction | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Bronchopleural fistula | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Chronic obstructive pulmonary disease | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Dyspnoea | 5 (2.0%) | 1 (0.4%) | 0 (0.0%) |
| Epistaxis | 2 (0.8%) | 1 (0.4%) | 0 (0.0%) |
| Haemoptysis | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Immune-mediated lung disease | 1 (0.4%) | 1 (0.4%) | 0 (0.0%) |
| Laryngeal stenosis | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Obstructive airways disorder | 0 (0.0%) | 2 (0.8%) | 0 (0.0%) |
| Oropharyngeal fistula | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Oropharyngeal pain | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Pharyngeal haemorrhage | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Pharyngeal inflammation | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Pleural effusion | 1 (0.4%) | 1 (0.4%) | 0 (0.0%) |
| Pleurisy | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Pneumomediastinum | 0 (0.0%) | 1 (0.4%) | 0 (0.0%) |
| Pneumonitis | 3 (1.2%) | 6 (2.4%) | 0 (0.0%) |
| Pneumothorax | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Pulmonary embolism | 1 (0.4%) | 2 (0.8%) | 0 (0.0%) |
| Pulmonary haemorrhage | 1 (0.4%) | 1 (0.4%) | 0 (0.0%) |
| Respiratory failure | 3 (1.2%) | 1 (0.4%) | 0 (0.0%) |
| Tracheal fistula | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Drug eruption | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Skin ulcer | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Arterial haemorrhage | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Embolism | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Hypertension | 3 (1.2%) | 0 (0.0%) | 0 (0.0%) |
| Hypotension | 3 (1.2%) | 0 (0.0%) | 0 (0.0%) |
| Orthostatic hypotension | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) |
| Total events | 293 | 131 | 0 |
Other Adverse Events (64)
| Event | Pembrolizumab + Lenvatinib First Course (n=254) | Pembrolizumab + Placebo (n=253) | Pembrolizumab + Lenvatinib Second Course (n=2) |
|---|---|---|---|
| Anaemia | 65 (25.6%) | 51 (20.2%) | 0 (0.0%) |
| Ear pain | 6 (2.4%) | 2 (0.8%) | 1 (50.0%) |
| Hyperthyroidism | 19 (7.5%) | 10 (4.0%) | 0 (0.0%) |
| Hypothyroidism | 124 (48.8%) | 43 (17.0%) | 0 (0.0%) |
| Bowel movement irregularity | 0 (0.0%) | 0 (0.0%) | 1 (50.0%) |
| Constipation | 56 (22.0%) | 46 (18.2%) | 0 (0.0%) |
| Diarrhoea | 71 (28.0%) | 33 (13.0%) | 1 (50.0%) |
| Dry mouth | 17 (6.7%) | 18 (7.1%) | 0 (0.0%) |
| Dyspepsia | 14 (5.5%) | 3 (1.2%) | 0 (0.0%) |
| Dysphagia | 35 (13.8%) | 14 (5.5%) | 0 (0.0%) |
| Flatulence | 2 (0.8%) | 1 (0.4%) | 1 (50.0%) |
| Nausea | 62 (24.4%) | 25 (9.9%) | 0 (0.0%) |
| Oral pain | 29 (11.4%) | 6 (2.4%) | 0 (0.0%) |
| Stomatitis | 53 (20.9%) | 12 (4.7%) | 0 (0.0%) |
| Vomiting | 33 (13.0%) | 14 (5.5%) | 0 (0.0%) |
| Asthenia | 26 (10.2%) | 25 (9.9%) | 1 (50.0%) |
| Fatigue | 80 (31.5%) | 41 (16.2%) | 1 (50.0%) |
| Mucosal inflammation | 25 (9.8%) | 7 (2.8%) | 0 (0.0%) |
| Pyrexia | 20 (7.9%) | 19 (7.5%) | 0 (0.0%) |
| COVID-19 | 16 (6.3%) | 13 (5.1%) | 0 (0.0%) |
| Pneumonia | 25 (9.8%) | 11 (4.3%) | 0 (0.0%) |
| Urinary tract infection | 13 (5.1%) | 13 (5.1%) | 0 (0.0%) |
| Alanine aminotransferase increased | 36 (14.2%) | 21 (8.3%) | 0 (0.0%) |
| Amylase increased | 14 (5.5%) | 14 (5.5%) | 0 (0.0%) |
| Aspartate aminotransferase increased | 37 (14.6%) | 23 (9.1%) | 0 (0.0%) |
| Blood alkaline phosphatase increased | 13 (5.1%) | 19 (7.5%) | 0 (0.0%) |
| Blood bilirubin increased | 17 (6.7%) | 7 (2.8%) | 0 (0.0%) |
| Blood creatinine increased | 26 (10.2%) | 5 (2.0%) | 0 (0.0%) |
| Blood thyroid stimulating hormone increased | 16 (6.3%) | 7 (2.8%) | 0 (0.0%) |
| Lipase increased | 30 (11.8%) | 17 (6.7%) | 0 (0.0%) |
| Lymphocyte count decreased | 30 (11.8%) | 20 (7.9%) | 0 (0.0%) |
| Platelet count decreased | 31 (12.2%) | 8 (3.2%) | 0 (0.0%) |
| Weight decreased | 65 (25.6%) | 39 (15.4%) | 0 (0.0%) |
| White blood cell count decreased | 16 (6.3%) | 10 (4.0%) | 0 (0.0%) |
| Decreased appetite | 57 (22.4%) | 23 (9.1%) | 1 (50.0%) |
| Hypercalcaemia | 11 (4.3%) | 18 (7.1%) | 0 (0.0%) |
| Hyperglycaemia | 14 (5.5%) | 11 (4.3%) | 0 (0.0%) |
| Hyperkalaemia | 18 (7.1%) | 7 (2.8%) | 0 (0.0%) |
| Hypoalbuminaemia | 34 (13.4%) | 23 (9.1%) | 0 (0.0%) |
| Hypokalaemia | 22 (8.7%) | 9 (3.6%) | 0 (0.0%) |
| Hypomagnesaemia | 22 (8.7%) | 7 (2.8%) | 0 (0.0%) |
| Hyponatraemia | 44 (17.3%) | 28 (11.1%) | 0 (0.0%) |
| Hypophosphataemia | 14 (5.5%) | 3 (1.2%) | 0 (0.0%) |
| Arthralgia | 40 (15.7%) | 18 (7.1%) | 0 (0.0%) |
| Musculoskeletal chest pain | 8 (3.1%) | 3 (1.2%) | 1 (50.0%) |
| Neck pain | 18 (7.1%) | 8 (3.2%) | 0 (0.0%) |
| Dizziness | 13 (5.1%) | 8 (3.2%) | 0 (0.0%) |
| Headache | 32 (12.6%) | 16 (6.3%) | 0 (0.0%) |
| Insomnia | 25 (9.8%) | 12 (4.7%) | 0 (0.0%) |
| Haematuria | 13 (5.1%) | 7 (2.8%) | 0 (0.0%) |
| Proteinuria | 62 (24.4%) | 16 (6.3%) | 0 (0.0%) |
| Cough | 40 (15.7%) | 23 (9.1%) | 1 (50.0%) |
| Dysphonia | 23 (9.1%) | 4 (1.6%) | 0 (0.0%) |
| Dyspnoea | 25 (9.8%) | 14 (5.5%) | 0 (0.0%) |
| Haemoptysis | 10 (3.9%) | 10 (4.0%) | 1 (50.0%) |
| Oropharyngeal pain | 28 (11.0%) | 8 (3.2%) | 0 (0.0%) |
| Pneumonitis | 11 (4.3%) | 10 (4.0%) | 1 (50.0%) |
| Productive cough | 17 (6.7%) | 6 (2.4%) | 0 (0.0%) |
| Dry skin | 15 (5.9%) | 8 (3.2%) | 0 (0.0%) |
| Palmar-plantar erythrodysaesthesia syndrome | 36 (14.2%) | 2 (0.8%) | 0 (0.0%) |
| Pruritus | 27 (10.6%) | 29 (11.5%) | 0 (0.0%) |
| Rash | 34 (13.4%) | 23 (9.1%) | 0 (0.0%) |
| Hypertension | 117 (46.1%) | 24 (9.5%) | 0 (0.0%) |
| Hypotension | 14 (5.5%) | 7 (2.8%) | 1 (50.0%) |
Additional Information
PI is Sponsor Employee: No
Point of Contact
- Title: Senior Vice President, Global Clinical Development
- Organization: Merck Sharp & Dohme LLC
- Email: ClinicalTrialsDisclosure@msd.com
- Phone: 1-800-672-6372
IPD Sharing Statement
IPD Sharing: YES
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
URL: https://externaldatasharing-msd.com/
Documents & Links
Study Documents
| Document Type | Date | Size | Filename |
|---|---|---|---|
| Protocol, SAP, Prot_SAP | 2023-10-19 | 1,429,816 bytes | Prot_SAP_000.pdf |
References (1)
- [1] Taylor MH, Schmidt EV, Dutcus C, Pinheiro EM, Funahashi Y, Lubiniecki G, Rasco D. The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol. 2021 Feb;17(6):637-648. doi: 10.2217/fon-2020-0937. Epub 2020 Dec 10. (PMID: 33300372) [DERIVED]